¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(-2034³â) : À¯Çü, Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ±â¼ú, ÇÁ·Î¼¼½º, ±¸¼º ¿ä¼Ò, ´Ü°è, ¼­ºñ½º, µð¹ÙÀ̽º
Biosimilars Market Analysis and Forecast to 2034: Type, Product, Application, End User, Technology, Process, Component, Stage, Services, Device
»óǰÄÚµå : 1762088
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 390 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,582,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 7,968,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,354,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº 2024³â 240¾ï ´Þ·¯¿¡¼­ 2034³â±îÁö´Â 1,177¾ï ´Þ·¯·Î È®´ëµÇ¸ç ¾à 17.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀå¿¡´Â ÀÌ¹Ì ½ÂÀÎµÈ ±âÁØ Á¦Ç°°ú À¯»ç¼ºÀÌ ³ô°í, ¾ÈÀü¼º°ú È¿´É¿¡ ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â Â÷À̰¡ ¾ø´Â »ý¹°ÇÐÀû Á¦Á¦°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²Àû, Àú·ÅÇÑ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¾÷°è °³¿ä

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ¼¼°èÀÇ °ü¼¼, ÁöÁ¤ÇÐÀû ±äÀå, ÁøÈ­ÇÏ´Â °ø±Þ¸Á ¿ªÇÐ µî º¹ÀâÇÑ Á¤¼¼¸¦ ±Øº¹Çϰí ÀÖ½À´Ï´Ù. ¿µÇâÀ» ¿ÏÈ­ÇÏ°í ¿Ü±¹Á¦ »ý¹°Á¦Á¦¿¡ ´ëÇÑ ÀÇÁ¸À» ÁÙÀ̰í ÀÖ½À´Ï´Ù. ÇÑÆí, ¹Ì±¹°ú Áß±¹ÀÇ ¸¶Âû ¼Ó¿¡¼­ ÁöÁ¤ÇÐÀû Ãë¾à¼º¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀûÀ¸·Î º¸¸é, ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº »ý¹°Á¦Á¦¸¦ ´ëüÇÏ´Â ºñ¿ë ´ëºñ È¿°úÀûÀÎ ´ëüǰ°ú °í·ÉÈ­¿¡ ÀÇÇØ ȰȲÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¿ªµ¿ÀûÀÎ °ø±Þ¸Á°ú Àü·«Àû Á¦ÈÞ¸¦ Á¶°ÇÀ¸·Î ½ÃÀåÀº Å©°Ô È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çü ÀçÁ¶ÇÕ ´çÈ­ ´Ü¹éÁú, ÀçÁ¶ÇÕ ºñ´çÈ­ ´Ü¹éÁú, ÆéŸÀ̵å
Á¦Ç° ´ÜŬ·ÐÇ×ü, Àν¶¸°, ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾, °ú¸³±¸Áý·«ÀÚ±ØÀÎÀÚ, Àΰ£¼ºÀåÈ£¸£¸ó, ÀÎÅÍÆä·Ð, ºÒÀÓÈ£¸£¸ó
¿ëµµ Á¾¾çÇÐ, ¸¸¼º Áúȯ, ÀÚ°¡ ¸é¿ª Áúȯ, Ç÷¾× Áúȯ, Àü¿°º´, ¼ºÀå È£¸£¸ó °áÇÌ
ÃÖÁ¾ »ç¿ëÀÚ º´¿ø, Ŭ¸®´Ð, ¿¬±¸ ±â°ü, Á¦¾à ȸ»ç, »ý¸í °øÇРȸ»ç
±â¼ú ÀçÁ¶ÇÕ DNA ±â¼ú, ´ÜÀÏŬ·ÐÇ×ü ±â¼ú, ´Ü¹éÁú ½ÃÄö½Ì, »ý¹°Á¤º¸ÇÐ
ÇÁ·Î¼¼½º ¾÷½ºÆ®¸² ó¸®, ´Ù¿î½ºÆ®¸² ó¸®
±¸¼º ¿ä¼Ò ¿ø·áÀǾàǰ(API), ¿ÏÁ¦Ç° Á¦Çü
´Ü°è ÀÓ»ó½ÃÇè, ÀüÀӻ󿬱¸, »ó¾÷È­
¼­ºñ½º °è¾à Á¦Á¶, °è¾à ¿¬±¸, ±ÔÁ¦ ÄÁ¼³ÆÃ
ÀåÄ¡ »ý¹°¹ÝÀÀ±â, Å©·Î¸¶Åä±×·¡ÇÇ ½Ã½ºÅÛ

½ÃÀå °³¿ä :

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ÁÖ·Î ºñ¿ëÈ¿°ú°¡ ³ôÀº »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡¿Í ¼±¹ß»ý¹° Á¦Á¦ÀÇ Æ¯Çã ¸¸·á¿¡ ÈûÀÔ¾î °ßÁ¶ÇÑ È®´ë¸¦ °è¼ÓÇϰí ÀÖ½À´Ï´Ù. °ßÀÎ ¾Ï ¿µ¿ªÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯´Â »ó´çÇÑ ºñ¿ë Àý°¨°ú µ¿µîÇÑ È¿°ú¸¦ Á¦°øÇϱâ À§ÇØ °Ç°­ °ø±ÞÀÚ¿Í ÁöºÒÀÚ¿¡°Ô ¸Å¿ì ¸Å·ÂÀûÀÔ´Ï´Ù. ½Ã¹Ð·¯ÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀ̳ª ´ç´¢º´ µîÀÇ »õ·Î¿î ÇÏÀ§ ºÎ¹®Àº ÀÌ·¯ÇÑ ÁúȯÀÇ ÀÌȯÀ²ÀÌ »ó½ÂÇØ, Àǻ糪 ȯÀÚÀÇ »çÀÌ¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ¹Þ¾Æµé¿©Áö°í Àֱ⠶§¹®¿¡ ´ëÆøÀûÀÎ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÚ°¡¸é¿ªÁúȯ ºÐ¾ß´Â ´ÜÀÏŬ·ÐÇ×üÀÇ ±â¼ú Çõ½Å°ú Â÷¼¼´ë ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ °³¹ß·ÎºÎÅÍ ÇýÅÃÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, À̷νá ȯÀÚÀÇ ¿¹ÈÄ °³¼±°ú Ä¡·á ¼±ÅÃÀÇ È®´ë°¡ ±â´ëµÇ¾î ½ÃÀå ¿ªÇп¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

Ãæµ¹ °³¿ä :

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ¿ªµ¿ÀûÀÎ ½ÃÀå Á¡À¯À² ºÐÆ÷°¡ Ư¡À̸ç, ¾Ï ÀÌȯÀ² Áõ°¡¿Í ºñ¿ë È¿À²ÀûÀÎ ´ëü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä·ÎºÎÅÍ ¾Ï ¿µ¿ªÀÌ µ¹ÃâÇÑ ¸®´õ·Î¼­ ´ëµÎÇϰí ÀÖ½À´Ï´Ù. ¸é¿ªºÐ¾ß´Â ÀÚ°¡¸é¿ªÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡Çϰí ÀÌ¿¡ µû¸¥ Ä¡·á ¿É¼ÇÀÇ Çʿ伺¿¡ µû¶ó ¾à°£ÀÇ Â÷À̰¡ ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â À¯·´ÀÌ È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú ³ôÀº º¸±Þ·ü¿¡ ÀÇÇØ ½ÃÀåÀÇ ÁÖµµÀû ÁöÀ§¸¦ À¯ÁöÇϰí ÀÖ´Â ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡¿Í Á¤ºÎÀÇ Áö¿øÃ¥¿¡ µÞ¹ÞħµÇ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¾÷°èÀÇ ÁÖ¿ä ±â¾÷Àº ÀÌ ±Þ¼ºÀå ½ÃÀå¿¡¼­ ´õ Å« Á¡À¯À²À» ¾ò±â À§ÇØ Àü·«Àû Á¦ÈÞ ¹× Á¦Ç° »ó½Ã¸¦ ÅëÇØ Àû±ØÀûÀ¸·Î Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå °æÀï ±¸µµ´Â ƯÈ÷ ¾ö°ÝÇÑ ½ÂÀÎ ÇÁ·Î¼¼½º°¡ Á¦Ç°ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÏ´Â À¯·´ ¹× ºÏ¹Ì¿Í °°Àº Áö¿ª¿¡¼­ ±ÔÁ¦ÀÇ ¿µÇâÀ¸·Î Å©°Ô Çü¼ºµË´Ï´Ù. Amgen, Sandoz, Pfizer µîÀÇ ±â¾÷µéÀÌ ÃÖÀü¼±¿¡ ¼­¼­ ±¤¹üÀ§ÇÑ Á¶»ç ´É·Â°ú Àü·«Àû Á¦ÈÞ¸¦ Ȱ¿ëÇÏ¿© °æÀï ¿ìÀ§¸¦ ȹµæÇϰí ÀÖ½À´Ï´Ù. ¾ÕÀ¸·Î´Â ¸î °¡Áö Å« È÷Æ® »ý¹° Á¦Á¦ÀÇ Æ¯Çã°¡ ²÷¾îÁ® ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ »çÀÌ¿¡ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ¹Þ¾Æµé¿©Áö°í ÀÖ´Â °ÍÀÌ ÃßdzÀÌ µÇ¾î ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ±×·¯³ª ÁöÀûÀç»ê±Ç ºÐÀï°ú ½ÃÀå ÁøÀÔ À庮°ú °°Àº °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. ±×·¯³ª »ý¸í°øÇÐÀÇ Áøº¸¿Í Áö¼ÓÀûÀÎ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀ¸·Î ½ÃÀå È®´ëÀÇ È£±â°¡ »ý±æ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ :

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ºí·Ï¹ö½ºÅÍ »ý¹°Á¦Á¦ÀÇ Æ¯Çã ¸¸·áÀ¸·Î ÀÎÇØ ½ÃÀåÀÌ ¹ÙÀÌ¿À½Ã¹Ð·¯ °æÀï¿¡ °³¹æµÇ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Ã¤ÅÃÀ» Àû±ØÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼úÇõ½ÅÀ» ÃËÁøÇÏ°í ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ Ãæ½Ç·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ »çÀÌ¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ÀÎÁöµµ¿Í ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾ïÁ¦¿äÀΰú µµÀü :

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡´Â ¸î °¡Áö Áß¿äÇÑ ¾ïÁ¦¿äÀΰú °úÁ¦°¡ ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷ÀÇ °æÁ¦Àû ºÎ´ãÀÌ ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Ã³¹æ¿¡ ´ëÇÑ ÀÇ»çÀÇ Àνİú ½Å·Ú°¡ ÇöÀúÈ÷ ºÎÁ·Çϰí, À̰ÍÀÌ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Ã¤¿ëÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ »ó½ÃÈÄÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» °¨½ÃÇϱâ À§ÇÑ °ß°íÇÑ ¾à¹°°¨½Ã ½Ã½ºÅÛÀÇ Çʿ伺Àº ¹°·ù¿Í ÀçÁ¤»óÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. Ƽ°¡ Á¤ÂøÇϰí Àֱ⠶§¹®¿¡ ¹ÙÀÌ¿À½Ã¹Ð·¯´Â ºñ¿ë¸é¿¡¼­ À¯¸®ÇÏ´Ù°í ÇØµµ ½ÃÀå Á¡À¯À²À» È®´ëÇÏ´Â °ÍÀÌ °ï¶õÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå Àü¸Á

Á¦5Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå Àü·«

Á¦6Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ±Ô¸ð

Á¦7Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : À¯Çüº°

Á¦8Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Á¦Ç°º°

Á¦9Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ¿ëµµº°

Á¦10Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ±â¼úº°

Á¦12Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦13Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ±¸¼º ¿ä¼Òº°

Á¦14Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ´Ü°èº°

Á¦15Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ¼­ºñ½ºº°

Á¦16Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : µð¹ÙÀ̽ºº°

Á¦17Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Áö¿ªº°

Á¦18Àå °æÀï ±¸µµ

Á¦19Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Biosimilars Market is anticipated to expand from $24.0 billion in 2024 to $117.7 billion by 2034, growing at a CAGR of approximately 17.3%. Biosimilars Market encompasses biologic medical products highly similar to already approved reference products, offering no clinically meaningful differences in safety or efficacy. This market is driven by patent expirations of biologics, cost-effectiveness, and increasing demand for affordable healthcare solutions. Regulatory frameworks in various regions are evolving to support biosimilar approvals, fostering innovation and competition. The market is poised for significant growth as healthcare systems seek to balance cost pressures with the need for advanced therapeutic options.

Industry Overview:

The biosimilars market is navigating a complex landscape of global tariffs, geopolitical tensions, and evolving supply chain dynamics. Japan and South Korea are strategically enhancing their biosimilar capabilities, leveraging innovation to mitigate tariff impacts and reduce dependency on foreign biologics. China's focus on self-reliance is intensifying, with state-backed initiatives fostering a robust domestic biosimilars sector. Taiwan, while pivotal in biopharmaceutical manufacturing, faces geopolitical vulnerabilities amidst US-China frictions. Globally, the biosimilars market is buoyant, driven by cost-effective alternatives to biologics and an aging population. By 2035, the market is poised for significant expansion, contingent on resilient supply chains and strategic alliances. Middle East conflicts, while primarily affecting energy prices, indirectly influence biosimilar production costs and distribution logistics worldwide.

Market Segmentation
TypeRecombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Peptides
ProductMonoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Human Growth Hormone, Interferons, Fertility Hormones
ApplicationOncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Infectious Diseases, Growth Hormone Deficiency
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Firms
TechnologyRecombinant DNA Technology, Monoclonal Antibody Technology, Protein Sequencing, Bioinformatics
ProcessUpstream Processing, Downstream Processing
ComponentActive Pharmaceutical Ingredients (API), Finished Dosage Formulations
StageClinical Trials, Preclinical Studies, Commercialization
ServicesContract Manufacturing, Contract Research, Regulatory Consulting
DeviceBioreactors, Chromatography Systems

Market Overview:

The Biosimilars Market is experiencing robust expansion, primarily fueled by the rising need for cost-effective biologic therapies and the expiration of patents for original biologics. The oncology segment leads the market, driven by the increasing prevalence of cancer and the high cost of reference biologics. Biosimilars in oncology offer significant cost savings and comparable efficacy, making them highly attractive to healthcare providers and payers. Furthermore, advancements in biologic drug development and manufacturing technologies enhance their adoption. Emerging sub-segments, such as autoimmune diseases and diabetes, are poised for substantial growth due to the rising incidence of these conditions and the growing acceptance of biosimilars among physicians and patients. The autoimmune segment, in particular, is expected to benefit from ongoing innovations in monoclonal antibodies and the development of next-generation biosimilars, which promise improved patient outcomes and expanded therapeutic options, thereby significantly impacting market dynamics.

Geographical Overview:

The biosimilars market is witnessing remarkable growth, with regional dynamics playing a pivotal role. In North America, the market is expanding due to a robust regulatory framework and increasing healthcare expenditure. The United States, a key player, is driving growth through strategic collaborations and a focus on reducing healthcare costs. Europe stands as a leader in the biosimilars market, propelled by supportive government policies and a strong emphasis on cost-effective healthcare solutions. The region's well-established pharmaceutical industry and high acceptance rates among healthcare professionals further contribute to its dominance. Germany and the United Kingdom are at the forefront. In Asia Pacific, the biosimilars market is experiencing rapid expansion. This growth is driven by a surge in chronic diseases and an aging population. Countries like China and India are investing heavily in biosimilar development and manufacturing. Their large patient pools and increasing healthcare access further bolster market potential. Latin America is an emerging market for biosimilars, with growing awareness and acceptance among healthcare providers. Brazil and Mexico are leading the way, focusing on regulatory improvements and cost-saving initiatives. The region's potential is significant, given its evolving healthcare landscape. The Middle East & Africa region is gradually recognizing the benefits of biosimilars. The market here is driven by the need to improve healthcare affordability and accessibility. Countries like Saudi Arabia and South Africa are making strides in adopting biosimilars to enhance healthcare outcomes and economic efficiency.

Competition Overview:

The biosimilars market is characterized by a dynamic distribution of market share, with the oncology segment emerging as a prominent leader due to the increasing prevalence of cancer and the demand for cost-effective treatment alternatives. The immunology segment follows closely, driven by the rising incidence of autoimmune diseases and the subsequent need for affordable therapeutic options. Geographically, Europe maintains a leadership position in the market due to its well-established regulatory framework and high adoption rates, while the Asia-Pacific region is witnessing robust growth fueled by increasing healthcare expenditure and supportive government initiatives. Key industry players are actively enhancing their portfolios through strategic collaborations and product launches to capture a larger share of this burgeoning market. The competitive landscape of the biosimilars market is shaped significantly by regulatory influences, particularly in regions like Europe and North America, where stringent approval processes ensure product safety and efficacy. Companies such as Amgen, Sandoz, and Pfizer are at the forefront, leveraging their extensive research capabilities and strategic alliances to gain competitive advantage. Looking ahead, the market is poised for substantial growth, driven by the expiration of patents for several blockbuster biologics and the increasing acceptance of biosimilars among healthcare providers and patients. However, challenges such as intellectual property disputes and market entry barriers persist. Nonetheless, advancements in biotechnology and ongoing regulatory support are expected to create lucrative opportunities for market expansion.

Recent Developments:

The biosimilars market has experienced notable developments in recent months. Amgen announced a strategic partnership with a leading European pharmaceutical company to co-develop and commercialize a new biosimilar targeting autoimmune diseases, aiming to expand their presence in the European market. In regulatory news, the U.S. FDA approved a groundbreaking biosimilar for treating cancer, marking a significant milestone in oncology therapeutics and potentially reducing treatment costs. Pfizer and Biocon Biologics entered a joint venture to enhance their biosimilars portfolio, focusing on emerging markets in Asia and Africa, which are projected to see substantial growth in demand. Market analysts reported a surge in biosimilars adoption in the European Union, driven by favorable regulatory policies and increased physician acceptance, which is expected to boost market growth. Lastly, a prominent South Korean biosimilar manufacturer announced a major investment to expand its production facilities, aiming to meet the growing global demand for cost-effective biologic treatments. These developments underscore the dynamic nature of the biosimilars market, highlighting opportunities for growth and innovation.

Key Companies:

Alvotech, Coherus Bio Sciences, Amgen, Samsung Bioepis, Celltrion, Biocon, Sandoz, Mylan, Fresenius Kabi, Stada Arzneimittel, Dr Reddy's Laboratories, Lupin, Hikma Pharmaceuticals, Apotex, Teva Pharmaceutical Industries, Zydus Cadila, Torrent Pharmaceuticals, Cadila Healthcare, Alkem Laboratories, Gedeon Richter

Key Trends and Drivers:

The biosimilars market is experiencing robust growth, propelled by the expiration of patents for blockbuster biologics, which opens the market to biosimilar competition. This trend is further driven by the increasing prevalence of chronic diseases, which necessitates cost-effective treatment options. Governments and healthcare providers are actively promoting the adoption of biosimilars to reduce healthcare expenditure. Technological advancements in the development and manufacturing of biosimilars are enhancing product quality and reducing time-to-market. This progress is crucial in gaining regulatory approval and fostering market acceptance. Additionally, the growing investment in research and development by key pharmaceutical companies is fueling innovation, leading to a broader pipeline of biosimilar products. The market is also witnessing increased collaborations and partnerships among pharmaceutical companies to leverage expertise and share resources. This trend is accelerating the development and commercialization of biosimilars, thus expanding market reach. Moreover, the rising awareness and acceptance of biosimilars among healthcare professionals and patients are driving market demand. As biosimilars continue to gain traction, opportunities abound in emerging markets where healthcare infrastructure is rapidly evolving, presenting significant growth potential for industry players.

Restraints and Challenges:

The biosimilars market encounters several significant restraints and challenges. A primary challenge is the regulatory complexity and variability across regions, which can delay approvals and increase costs. This complexity often necessitates extensive clinical trials, adding to the financial burden on manufacturers. Furthermore, there is a notable lack of physician awareness and confidence in prescribing biosimilars, which hampers their adoption. Intellectual property disputes, including patent litigations, can also obstruct market entry and expansion. Additionally, the need for robust pharmacovigilance systems to monitor biosimilar safety and efficacy post-launch poses logistical and financial challenges. Lastly, the entrenched brand loyalty to original biologics makes it difficult for biosimilars to gain market share, despite their cost advantages. These factors collectively impede the swift growth and broader acceptance of biosimilars in the healthcare market.

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Biosimilars Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Biosimilars Market Outlook

5: Biosimilars Market Strategy

6: Biosimilars Market Size

7: Biosimilars Market, by Type

8: Biosimilars Market, by Product

9: Biosimilars Market, by Application

10: Biosimilars Market, by End User

11: Biosimilars Market, by Technology

12: Biosimilars Market, by Process

13: Biosimilars Market, by Component

14: Biosimilars Market, by Stage

15: Biosimilars Market, by Services

16: Biosimilars Market, by Device

17: Biosimilars Market, by Region

18: Competitive Landscape

19: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â